Training Materials

Understanding Your Glucose Using Real-Time CGM: A Playbook for your Health

OlgaDalisay — Mon, 07 Aug 2023 20:20:23 +0000

Understanding Your Glucose Using Real-Time CGM: A Playbook for your Health

08/07/2023

OlgaDalisay Mon, 08/07/2023 - 20:20

New Resource for You and Your Patients!

This new educational resource presents the reader with an engaging dialogue between main characters - cousins Joe and Joanne, who both live with Type 2 diabetes. Though they manage their diabetes differently, they face the same challenges when it comes to staying in target glucose range. Their discovery of the RT-CGM enables them to live better lives and take control of their diabetes.

This is an excellent resource to work with your patients to introduce them to CGM and the basics of data interpretation.

About the Author

This playbook was developed in collaboration with Gary Scheiner, MS, CDCES, Owner and Clinical Director, Integrated Diabetes Services.

Gary is a Certified Diabetes Care and Education Specialist in private practice and author of “Think Like a Pancreas” and “Practical CGM.” He was named Diabetes Educator of the Year in 2014 and has lived a positive life with diabetes since 1985.

Training Materials

Training Materials - Downloads

T2D

LBL-1003949 Dexcom T2 Playbook for Your Health.pdf

Related Resources

CGM 101: Resources for Patients

Premium Content

Off

Pharmacist Training Videos

alexa.stelzer — Mon, 09 Dec 2024 19:49:23 +0000

Pharmacist Training Videos

12/08/2024

alexa.stelzer Mon, 12/09/2024 - 19:49

Pharmacists play a crucial role in diabetes management. This video series introduces pharmacists to the Dexcom G7 Continuous Glucose Monitoring (CGM) system. Video 1 compares glucose monitoring devices, explores app features, and discusses user resources. Video 2 details how to get patients started on the Dexcom G7 CGM.

Video 1: Information for Pharmacists

Video 2: Getting Patients Started

Training Materials

Expert Presentations

Related Resources

Podcast Episode 22: Revolutionizing Hospital Discharge Planning with CGM Technology

CGM 101: Resources for Patients

Premium Content

New Way for Patients to Share Glucose Data with Clarity Clinic

alexa.stelzer — Thu, 31 Oct 2024 17:30:49 +0000

New Way for Patients to Share Glucose Data with Clarity Clinic

11/04/2024

alexa.stelzer Thu, 10/31/2024 - 17:30

What Healthcare Providers Need to Know About the Clarity Clinic Connection within the Dexcom G7 App

Through a software update, Dexcom G7 users can now easily share glucose data with the healthcare team through the Dexcom G7 App.

Through a software update, Dexcom G7 users can now easily share glucose data with the healthcare team through the Dexcom G7 App.* Setting up data sharing is straightforward, and once connected, the data transfer is automatic. This new, simplified method of sharing glucose data ensures that you have the most up-to-date information to support your patients. †

How Patients Can Start Sharing Data Through the Dexcom G7 App

Provide your patient with your Clarity Clinic Code and encourage the Dexcom user to follow these simple steps.

To Begin Sharing Dexcom G7 Data, encourage Dexcom users to:

Open the Dexcom G7 App: Open the Dexcom G7 app on their smartphone.
Navigate to Connections: Tap on the Connections tab within the app.
Select Clarity Clinic: Choose the Clarity Clinic option and tap “Continue”.
Enter Clinic Code: Input the Clarity Clinic Code (provided by healthcare provider).
Confirm Details: Verify the clinic details and tap “Done” to complete the setup.

Providers can also share the Dexcom Help Page: "Setting up Dexcom Clarity” which provides step-by-step instructions on how to start sharing their data with the G7 App.

Once these steps are completed, your patient’s Dexcom G7 data will be shared with your clinic automatically. This connection allows continuous glucose data transfer and remains active until the patient or clinician decides to stop sharing. This same simplified data sharing experience is coming soon to Stelo by Dexcom.

Benefits of Using Clarity Clinic in Your Practice

Clarity Clinic enables you to view your patients’ retrospective glucose data and allows identification of glucose patterns and trends. The benefits of viewing your patient’s glucose data through Dexcom Clarity are multifaceted:

Patients who interact with CGM data show improved outcomes for both metabolic and diabetes distress symptoms.1, 2 The ability to view shared glucose data enables superior communication and can foster improved collaboration between those living with diabetes and the healthcare team.
Treatment plans can quickly and effectively be fine-tuned for each individual.

This integration not only simplifies the process of data sharing but also empowers your patients to take a more active role in their health care.

Dexcom Clarity Resources

For Providers:

For Patients:

Using Clarity Guide for Patients

*Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility.

† Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/registration.

References

Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022;45(3):750-753. doi:10.2337/dc21-2004

Crawford MA, Hicks, C, Genge P, Greenawald K, Tressler M, Cherñavvsky DR, Singh H. 677-P: Exploring the Impact of CGM on Perceived Control of Non-Intensive Insulin Treated Type 2 Diabetes - "I liked keeping my line with as few spikes as possible". Diabetes. 2023;72:677. doi:10.2337/db23-677-P

MAT-6244

Training Materials

Training Materials - Downloads

Related Resources

Dexcom G7 Direct to Apple Watch Now Available in the US

Glooko Enhances Transmitters for Direct Uploads from All Dexcom Receivers

Premium Content

Off

New Video Series: Your Journey with Stelo Towards Glucose Health

alexa.stelzer — Wed, 23 Oct 2024 21:38:18 +0000

New Video Series: Your Journey with Stelo Towards Glucose Health

11/06/2024

alexa.stelzer Wed, 10/23/2024 - 21:38

Help Patients Turn Personalized Glucose Insights Into Action

Staying informed about the latest advancements in glucose sensing technology, including over-the-counter (OTC) options, is crucial for healthcare providers. Equally important is having resources to share with patients, helping them understand and effectively use these technologies.

To support healthcare providers and patients, Dexcom has released a new video series that shares tips and tricks for using Stelo, the first OTC glucose biosensor. The 6-part series features advice from certified diabetes specialists and real-life experiences of Stelo users. View the videos below or click here to access and share the complete Stelo Video Gallery. It is recommended that the videos be viewed in order.

How Stelo Helps You

This introductory video explains how Stelo allows patients to see the impact of food and activity on their glucose levels, empowering them to make healthier choices.

Watch and Learn

A healthcare provider shares recommendations on how to get started with Stelo, including the optimal times to check glucose levels around meals and physical activity.

How to Lower Post-Meal Glucose

Practical tips from Stelo users on making small adjustments to eating habits to maintain healthier post-meal glucose levels.

How Physical Activity Can Affect Your Glucose

Insights into how different types of physical activity impact glucose levels and how to set achievable health goals.

How Sleep and Stress Can Affect Your Glucose

Information on how stress and sleep affect glucose levels and how to use Stelo to make persanolized changes for better sleep and stress management.

Putting It All Together

Users share the most impactful changes Stelo has helped them make, along with discussions on common questions such as why glucose levels might be higher in the morning and what to do when glucose drops below 70.

Learn More About Dexcom's Product Portfolio

For healthcare providers interested in learning more about Dexcom's product portfolio, including Stelo, additional information is available on provider.dexcom.com.

OTC Glucose Sensing

Training Materials

Expert Presentations

Related Resources

Stelo: Personalizing Choices, Revolutionizing Glucose Health

ATTD 2024 Symposia: CGM Improves Outcomes in Non-Insulin Treated Type 2 Diabetes

Premium Content

Off

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

OlgaDalisay — Wed, 19 Jun 2024 01:25:03 +0000

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

06/21/2024

OlgaDalisay Wed, 06/19/2024 - 01:25

Insulet has announced two important innovations for their Ominpod® 5 automated insulin delivery (AID) system:

Omnipod 5 integration with Dexcom G7 Sensor: This new feature will become broadly available over the coming months.
Omnipod 5 App for iPhone with Dexcom G6 recently started a limited market release with availability expected later this year.

The Omnipod 5 system’s integration with the Dexcom G7 requires a new Pod, one which is compatible with both the Dexcom G6 and G7 sensors.

Important Information for Starting Patients on Omnipod 5 with Dexcom G7 Sensor:

This Pod will have the same National Drug Code (NDC) as current Pods, which minimizes burden on clinic staff and means patients with Dexcom G6 insurance coverage for Pods will have Dexcom G7 insurance coverage for Pods. However, building up inventory of this new Pod in retail pharmacies across the nation will take some time. For access, please see the information below.

For Patients Currently Using Multiple Daily Injections (MDI) or Tubed Pumps:

To initiate a patient on the Dexcom G7, prescribe the Omnipod 5 Intro Kit and Pods exclusively through ASPN Pharmacies. ASPN will ensure new Omnipod patients receive the Dexcom G6/G7 compatible Pods.
Detailed instructions are available here on how to prescribe Omnipod 5 with Dexcom G7.

For Current Omnipod 5 Patients:

No new Pod prescription or prior authorization is required for patients already using Omnipod 5.
Existing Omnipod 5 users will receive a free software update the week of July 29th, enabling them to pair a Dexcom G7 with a compatible Pod. Patients will be notified when the update is available, along with detailed instructions.
Advise patients to continue using their Dexcom G6 supplies until they receive Pods labeled "Compatible with Dexcom G7" on their refill box.
Once patients see the "Compatible with Dexcom G7" label, prescribe the Dexcom G7 sensor.

iPhone Control with Omnipod 5 and Dexcom G6 Sensor:

The Omnipod 5 App for iPhone will initially launch with the Dexcom G6 sensor. Therefore, current patients preferring iPhone control should continue using the Dexcom G6 sensor.
For new patients desiring iPhone control, prescribe Omnipod 5 with Dexcom G6 as usual.

These updates aim to enhance patient care by integrating the latest technology seamlessly into the Omnipod 5 system.

Please review this information carefully and ensure your patients are informed of these exciting advancements.

For more information on the latest clinical evidence on the use of a tubeless insulin delivery system, check out this Research Spotlight article

For more information about these updates, visit Omnipod’s FAQs: G7 FAQs and iPhone FAQs.

© 2024 Insulet Corporation. Omnipod, and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Dexcom, Dexcom G6, and Dexcom G7 are registered trademarks of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

Clinical Evidence

Clinical Evidence - Automated Insulin Delivery

Training Materials

Related Resources

New Episodes Alert: Beyond the Bolus Podcast

Two Years with a Tubeless Automated Insulin Delivery System

Premium Content

Revolutionizing Diabetes Care: Advances in Automated Insulin Delivery Systems

OlgaDalisay — Wed, 19 Jun 2024 01:22:13 +0000

Revolutionizing Diabetes Care: Advances in Automated Insulin Delivery Systems

06/21/2024

OlgaDalisay Wed, 06/19/2024 - 01:22

The iLet Bionic Pancreas is designed to simplify and enhance glucose management. This automated insulin delivery (AID) system leverages advanced algorithms to deliver insulin doses tailored to the user's needs. By continuously monitoring glucose levels and adjusting insulin delivery in real-time, the iLet Bionic Pancreas aims to improve glycemic control and reduce the burden of diabetes management for patients.

Beat Bionics announced new updates for the iLet Mobile App - an integral component of the iLet Bionic Pancreas system that provides users with seamless and intuitive access to their diabetes management data.

Patients can now monitor their status conveniently through the app without needing to access their iLet device directly. However, please advise them to keep their alarms active, as these will only be displayed on the iLet device.

NEW iLet Mirror Display

The iLet Mobile App now allows patients to view their iLet home screen in real time on their smartphones. The app displays:

CGM glucose levels and trends
Insulin cartridge level
Battery level
Charts for the past 24 hours of CGM data and insulin dosing

NEW Pause Insulin Feature

The iLet system now includes a feature that enables patients to pause insulin delivery during activities such as showering, exercising, or swimming, preventing insulin wastage when disconnected from the device. Please ensure your patients are aware of the following:

They will be prompted to set a timer to remind them to resume insulin delivery.
An Insulin Paused banner will appear on the home screen when insulin delivery is paused.
After completing the activity, patients can resume insulin by tapping the Insulin Paused banner on the home screen or the Pause Insulin icon in the iLet Menu screen, then selecting Resume Delivery.
The iLet will remind them to resume insulin delivery after the timer expires, and they can resume directly from the reminder alert.

Secondary Target (formerly known as CGM Sleep Target)

The iLet device allows patients to set two different CGM targets over a 24-hour period. We recommend discussing with your patients before they make any adjustments to their CGM targets.

Please guide your patients through the update process for the iLet Mobile App to ensure they benefit from these new features. Click below for the instructions on how to update the app

How to update

^{Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at}^{https://www.betabionics.com/resources/user-guides/}^{or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to}^{www.betabionics.com/resources/safety}

^{DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.}

Clinical Evidence

Clinical Evidence - Automated Insulin Delivery

Training Materials

Related Resources

Podcast Episode 13: Beta Bionics iLet

Premium Content

CGM 101: Resources for Patients

OlgaDalisay — Thu, 07 Mar 2024 20:57:19 +0000

CGM 101: Resources for Patients

03/07/2024

OlgaDalisay Thu, 03/07/2024 - 20:57

At SIGMA we value your time and strive to help you deliver high-quality care, optimize practice workflows, and achieve better outcomes for both you and your patients.

Your meter measures glucose levels at a single moment in time, while CGM continually check glucose levels throughout the day and night and can alert you if your glucose levels go too high or too low.

This new resource provides an overview of Continuous Glucose Monitoring: what it is, how it works as well as useful tips on utilizing the features of a CGM system.

You can download this brochure and use it in:

Conversations with new patients on CGM
Conversations with patients who may be intimidated to try CGM
Empower more experienced CGM users to get the most out of their CGM system
Your clinic to educate new staff

Download Resource

Training Materials

Training Materials - Downloads

Data Interpretation

Training Resources

cgm-101-you-and-your-dexcom-g7..pdf

Related Resources

Understanding Your Glucose Using Real-Time CGM: A Playbook for your Health

Real-time CGM: The FIRST Tool for Managing Type 2 Diabetes

Premium Content

Off

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

OlgaDalisay — Tue, 27 Feb 2024 19:37:55 +0000

Systematic Review of Commercial Hybrid Closed-Loop AID Systems

02/27/2024

OlgaDalisay Tue, 02/27/2024 - 19:37

Despite advancements, many individuals with T1D struggle to maintain optimal glycemic control. Automated insulin delivery (AID) systems, particularly hybrid closed-loop (HCL) systems, aim to improve control and reduce burden by automating insulin delivery based on continuous glucose monitoring (CGM) data.

In this Research Spotlight we are highlighting a recent study:

Peacock, S., Frizelle, I. & Hussain, S. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Ther 14, 839–855 (2023). https://doi.org/10.1007/ s13300-023-01394-5

The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Studies focusing on single-hormone commercial hybrid AID systems, involving participants with T1D, and reporting endpoints related to glycemic control were included.

The following endpoints were the main focus of the review:

Participants with T1D
A1c levels
Diabetic ketoacidosis (DKA) events
% of Time in Range (TIR) / Change in TIR
Incidents of severe hypoglycemia

Commercial HCL systems effectively improve TIR and glycemic control in T1D, with minimal risk of severe hypoglycemia.

Studies showed that HCL systems generally improved time in range (TIR) and glycemic control without increasing severe hypoglycemia. Psychosocial outcomes, such as quality of life and treatment satisfaction, were generally positive.

Results (Glycemic Outcomes)

Commercial HCL AID Systems are effective and can improve TIR³
Improvements in glycemic control were shown without increasing the incidence of severe hypoglycemia
Glycemic outcomes supported by real-world studies and randomized control trials (psychosocial endpoints analyzed separately - showing generally positive outcomes, but more data needed)

Research Spotlight

Clinical Evidence

Clinical Evidence - Automated Insulin Delivery

Training Materials

Training Materials - Downloads

Clinical Evidence - Type 1 Diabetes

Training Resources

dexcom-infographic-aid-peacock-study-mat-1197.pdf

Country

United States

Yes

Related Resources

EASD 2023: Real-Time CGM Clinical Outcomes – The 7-Year COMISAIR Data

Advancing Use and Access of AID Systems in the United Kingdom

Premium Content

Impact of CGM on Perceived Control of Non-Intensive Insulin Treated Type 2 Diabetes

OlgaDalisay — Tue, 14 Nov 2023 00:38:05 +0000

Impact of CGM on Perceived Control of Non-Intensive Insulin Treated Type 2 Diabetes

11/14/2023

OlgaDalisay Tue, 11/14/2023 - 00:38

New qualitative study exploring impact of Real-Time Continuous Glucose Monitoring on psychosocial outcomes in users with Type 2 diabetes on non-intensive insulin therapy.*

Background

Increased perceived control is associated with improved confidence & motivation in regard to diabetes self care
Progression of type 2 diabetes (T2D) demands complex treatment modalities that may impair patient confidence & psychological health
Continuous glucose monitoring (CGM) provides access to glucose levels in real-time & for retrospective reflection with potential psychological benefits for T2D users^1,2

Aim

To understand how patients’ experiences and learnings from using CGM relate to their demographics and changes in psychosocial & glycemic metrics

Methods

Participants answered open-ended questions about their experiences using CGM (including behavior & emotional impact)
Qualitative data were analyzed using content analysis and inter-coder reliability
Participants were categorized based on reported changes to perceived control

Participant Demographics

Results

Perceived control is associated with confidence and motivation in regard to diabetes self-care. After 3 months of Dexcom CGM wear, most participants reported “high perceived control"
Dexcom CGM can lead to feelings of empowerment, emotional relief, and a heightened sense of diabetes management
Dexcom CGM provides valuable insights even to well informed users
In certain groups, wearing Dexcom CGM can decrease the emotional burden of diabetes

Download Resource

^{* study was conducted using Dexcom G6 CGM System. 1. Ehrhardt N, et al. JDST. 2019;13(2):271-275 2. Crawford M, et al. ATTD. 2022; Abstract #972}

Clinical Evidence

Clinical Evidence - Type 2 Diabetes

Training Materials

Training Materials - Downloads

Training Resources

MAT-0969 v1.0 Perceived Control study infographic.pdf

Margaret Crawford, MPH, PhD

Maggie has a PhD public health, focusing on health behavior, and also earned a masters in public health in epidemiology. Maggie's personal and career goal is to help people understand their physiology and behaviors to help them feel in control of managing their health.

Premium Content

Effectiveness of Continuous Glucose Monitoring (CGM) in Older Adults with Type 2 Diabetes Treated with Basal Insulin

OlgaDalisay — Wed, 20 Sep 2023 21:28:20 +0000

Effectiveness of Continuous Glucose Monitoring (CGM) in Older Adults with Type 2 Diabetes Treated with Basal Insulin

09/20/2023

OlgaDalisay Wed, 09/20/2023 - 21:28

Post-hoc analysis of the MOBILE study

Download File

Objective

To evaluate the effectiveness and safety of CGM in older adults with type 2 diabetes treated on basal insulin only in a post-hoc analysis of the MOBILE study.

Study Outcomes Measured

The primary outcomes measured were A1C, time in target glucose range of 70-180 mg/dL, time with glucose level at ≥250 mg/dL, and mean glucose level at 8 months.

Results

Primary outcome was the -1.08% reduction in A1C among CGM group in both age cohorts, compared to the Blood Glucose Monitoring (BGM) group, that had mean reductions of -0.38% for those ≥65 years*, and -0.73% for those <65 years.**
Participants ≥65 years on CGM had a mean increase in Time in Range (TIR) of 16% compared to their baseline levels, whereas the BGM group exhibited a mean TIR change of -5%. Adjusted difference, 19% (P<0.01).

Key Takeaways

Use of CGM is associated with greater A1C decrease than BGM alone in adults with T2D on basal insulin, regardless of their age.^1,2
Using CGM is beneficial for adults aged 65 and above who have type 2 diabetes (T2D) and struggle to control their glucose levels using only basal insulin.²
The improvements in glucose control seen with CGM are just as significant in older adults as they are in younger ones.¹

^{* adjusted difference= -0.65% (95% CI -1.49, 0.19) (p=0.13) ** adjusted difference= -0.35% ( 95% CI -0.77, 0.07) (p=0.10)}

^{† A1C was collected at randomization, month 3, and month 8 and measured at a central laboratory}

^{‡ Participants in the CGM group wore the device continuously up through 8 months, whereas participants in the BGM group wore a blinded CGM during the 10 days after the 3-month visit and 10 days leading up to the 8-month visit.}

^{1. Bao S, Bailey R, Calhoun P, Beck RW. Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin. Diabetes Technol Ther. 2022 May;24(5):299-306. doi: 10.1089/dia.2021.0494.}

^{2. Martens T, et al; MOBILE Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021 Jun 8;325(22):2262-2272. doi: 10.1001/jama.2021.7444. PMID: 34077499; PMCID: PMC8173473}

Clinical Evidence

Clinical Evidence - Type 2 Diabetes

Training Materials

Training Materials - Downloads

Training Resources

MAT-0331 mobile sub analysis infographic.pdf

Related Resources

Comparing Continuous Glucose Monitoring (CGM) and Blood Glucose Monitoring (BGM) in Adults with Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study)

ATTD 2024 Symposia: Making the Invisible Visible in Type 2 Diabetes

Premium Content

Off